22157.jpg
Global Antibiotic Resistance Market Report 2022: New Technologies and New Drugs are Under Development to Capture this Growing Market
14 avr. 2022 04h08 HE | Research and Markets
Dublin, April 14, 2022 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
22157.jpg
Global Antibiotic Resistance Markets Report 2021: Therapeutic Technology Development Opportunities by Pathogen and Therapy Type 2020-2024
31 août 2021 05h53 HE | Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type 2020 to 2024" report has been added to ResearchAndMarkets.com's offering. ...
Summit Master_rgb_png.png
Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
18 mai 2021 07h00 HE | Summit Therapeutics Inc.
Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738”), for development in the fight against...
ezgif.com-gif-maker.png
Entasis Therapeutics Announces Sulbactam-Durlobactam Expanded Access Program for Patients in the U.S.
26 janv. 2021 08h00 HE | Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
red.jpg
RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication
26 oct. 2020 09h00 HE | RedHill Biopharma Ltd.
 H. pylori eradication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial, with antibiotic resistance a contributing factor. Despite declining...
provectus_logo.jpg
Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee Health Science Center to Investigate Small Molecule Rose Bengal Disodium for Antibiotic Resistance
09 sept. 2020 08h00 HE | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Michio Kurosu, PhD, Professor,...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
03 sept. 2020 21h42 HE | BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance
11 mars 2020 13h00 HE | Deinove
DEINOVE passes the 2nd milestone of the AGIR program and receives €1.5m from Bpifrance The AGIR program, supported by the French Investments for the Future program, aims to accelerate new...
Phase Genomics Receives $1.5MM NIH Grant to Develop Fast and Affordable Commercial Antimicrobial Resistance Tracking Kit
08 janv. 2020 09h30 HE | Phase Genomics
SEATTLE, Washington, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Phase Genomics, Inc., the biotech leader providing proximity-ligation next-generation sequencing (NGS) solutions for metagenome assembly, today...
ezgif.com-gif-maker.png
Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer
30 oct. 2019 16h05 HE | Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat...